Antileishmanial Activities of Carvacrol Nanoencapsulate in Biopolymeric Nanoparticles
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202403341 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Joyce Cordeiro Borges und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Industrial Nanoscience and Nanobiotechnology (LANNI), Center for Biotechnology, Federal University of Paraiba, Castelo Branco, João Pes…. Hauptthemen laut MEDLINE: Cymenes, Nanoparticles, Antiprotozoal Agents, Leishmania infantum. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PROPESQ/PRPG/UFPB.
Abstract (Originalsprache)
Visceral leishmaniasis (VL) is a neglected parasitic disease, and the first‐line treatments for VL include drugs that exhibit serious toxicological issues. In this sense, new molecules are sought for VL treatment, such as Carvacrol (Car), a phenolic monoterpene that has shown strong activity against Leishmania spp. However, its low solubility prevents its free administration, requiring a new therapeutic strategy such as encapsulation in chitosan biopolymeric nanoparticles. This study aimed to develop chitosan biopolymeric nanoparticles (NPChi) encapsulating Car (NPCar) and evaluate their in vitro anti‐leishmanial activity. The NPChi had particle sizes of 89.43 ± 0.774 nm, a polydispersity index (PDI) of 0.168 ± 0.01 and zeta potential of 12.8 ± 2.17 mV. The NPCar showed particle size of 144.9 ± 1.7 nm, PDI of 0.224 and zeta potential of 15.7 ± 1.01 mV. NPCar reduced the cytotoxicity of Car on human erythrocytes. Moreover, NPCar showed inhibition of Leishmania infantum with an inhibitory concentration (IC 50 ) of 2.659 ± 0.26 µg/mL. Thus, NPCar exhibited enhanced anti‐leishmanial activity compared to free Car while reducing cytotoxicity on human erythrocytes, making them promising candidates for further studies on VL treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Industrial Nanoscience and Nanobiotechnology (LANNI), Center for Biotechnology, Federal University of Paraiba, Castelo Branco, João Pessoa, Paraiba, Brazil.
- Laboratory of Immunology of Infectious Diseases (LABIDIC), Center for Biotechnology, Federal University of Paraiba, Castelo Branco, João Pessoa, Paraiba, Brazil.
- Laboratory of Microbiology and Parasitology, Campus Ouricuri, University of Pernambuco, Ouricuri, Pernambuco, Brazil.
- Keizo Asami Institute (iLIKA), Federal University of Pernambuco, Recife, Pernambuco, Brazil.
ORCID-Profile: Elisângela Afonso de Moura Kretzschmar
Förderung
- PROPESQ/PRPG/UFPB
Zitieren
APA
Borges, J. C., Barros, A. B. C., Cardoso, L. L., Keesen, T. L. S., Campos, L. A. A., Cavalcanti, I. M. F., & Kretzschmar, E. A. M. (2025). Antileishmanial Activities of Carvacrol Nanoencapsulate in Biopolymeric Nanoparticles. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202403341
Vancouver
Borges JC, Barros ABC, Cardoso LL, Keesen TLS, Campos LAA, Cavalcanti IMF, et al. Antileishmanial Activities of Carvacrol Nanoencapsulate in Biopolymeric Nanoparticles. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202403341
BibTeX
@article{Borges2025,
author = {Borges, Joyce Cordeiro and Barros, Anne Beatriz Cunha and Cardoso, Leonardo Lima and Keesen, Tatjana de Lima Souza and Campos, Luís André de Almeida and Cavalcanti, Isabella Macário Ferro and Kretzschmar, Elisângela Afonso de Moura},
title = {Antileishmanial Activities of Carvacrol Nanoencapsulate in Biopolymeric Nanoparticles},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202403341}
}
EUVIMED